RVTY Reported this cycle

Revvity

Waltham, MA Life Science Tools & CRO

AI-generated · informational only · not investment advice · verify before relying.

Latest analysis

Updated Nov 3, 2026

Revvity Q3 2026: 7% Organic Growth and 29.4% Operating Margin Signal Transformation Inflection Point

Revvity delivered its strongest quarterly performance since its transformation, with 7% pro forma organic growth exceeding guidance by roughly 200 basis points and pro forma adjusted EPS of $1.37, $0.08 above the midpoint of expectations. Life sciences led at 9% organic growth — reagents up high single digits (its best performance in several years), instruments up strong mid single digits, and Signals software up high teens — while the diagnostics segment grew 5% organically. Full-year pro forma organic growth guidance was raised to 5% from an original 2%-3% outlook, and full-year pro forma adjusted EPS guidance was set at $5.40-$5.45, implying approximately 12% growth year over year per management's own characterization.

Tone: bullish

Revenue

$2.9B

RVTY 10-K · FY 2025

Employees

11,000

Revenue growth YoY

+4%

Headquarters

Waltham, MA

Profile

RVTY 10-K Item 1 · Feb 24, 2026

Revvity is a health science solutions company operating across two segments — Life Sciences and Diagnostics — serving pharmaceutical, biotech, academic, clinical, and government customers in more than 160 countries. The company provides instruments, reagents, software, and services spanning drug discovery, genomics, reproductive health, and immunodiagnostics. Its strategy combines organic R&D investment with acquisitions to expand capabilities in multi-omics, biomarker identification, imaging, and informatics.

Read filing description ↓

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. Our strategy is to develop and deliver innovative products, services and solutions in high-growth markets that utilize our knowledge and expertise to address customers' critical needs and drive scientific breakthroughs. To execute on our strategy and accelerate revenue growth, we focus on broadening our offerings through both the investment in research and development and the acquisition of innovative technology. Our strategy includes strengthening our position within key markets by expanding our global product and service offerings, maintaining superior product quality and driving an enhanced customer experience; attracting, retaining and developing talented and engaged employees; accelerating transformational innovation through both internal research and development and third-party collaborations and alliances; augmenting growth in both of our core business segments, Life Sciences and Diagnostics, through strategic acquisitions and licensing; advancing the use of Artificial Intelligence to further strengthen our differentiated offerings and to drive internal operating efficiencies; engraining focused operational excellence to improve organizational efficiency and agility; and taking a disciplined approach to capital allocation to support organic investments, pursue mergers and acquisitions and opportunistic share repurchase programs to drive shareholder value.

Primary products

Reagents
Instruments
Software
Technology and Licensing
Radiometric detection solutions
PhenoVue cellular imaging reagents

Business segments

Life Sciences Diagnostics

End markets

Pharmaceutical and biotechnology companies Laboratories Academic and research institutions Public health authorities Private healthcare organizations Doctors Government agencies Contract research organizations Hospitals Medical labs Clinicians Medical research professionals

Geographies

United States More than 160 countries

Named customers

Genomics England Sanofi (T1D assay collaboration)

“We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.” Competitive position, as stated in the filing

Revenue commentary · FY 2025

Total revenue increased by $101.1 million, or 4%, in fiscal year 2025 versus fiscal year 2024, with Life Sciences segment revenue up 2% and Diagnostics segment revenue up 5%.

The rest of RVTY is for subscribers

Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.

SeventhBiz analysis 6 signals 12 diligence answers 2 M&A transactions SWOT

View plans Sign in